Applications of 11A,16B,17,21-Tetrahydroxy-Pregna-1,4-Diene-3,20-Dione in Industrial Manufacturing

11A,16B,17,21-Tetrahydroxy-Pregna-1,4-Diene-3,20-Dione is an advanced steroid intermediate essential to several complex industrial processes. We supply this compound directly to large-scale API plants, regulated formulation sites, and specialty synthesis partners who demand high purity material with consistent batch-to-batch compliance for downstream value-added production. Below are major real-world manufacturing scenarios.

1. Corticosteroid Active Pharmaceutical Ingredient (API) Synthesis

Major pharmaceutical producers rely on this raw material in the late-stage synthesis of corticosteroid APIs. The compound introduces the necessary multi-hydroxyl functional pattern for the synthesis pathway of prednisolone and related glucocorticoids. It is directly used in reaction sequences that undergo selective hydrogenation, oxidation, and protection-deprotection steps before final crystallization and QC testing of the API. Chromatographic purity and known impurity thresholds are enforced at this stage to ensure qualification as a fit-for-purpose API intermediate under regulatory scrutiny.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for APIs
• European Pharmacopoeia (Ph. Eur.) monographs for steroids
• US FDA cGMP 21 CFR Part 210/211
• Certificate of Suitability (CEP) where required

Typical usage ratio

• Usually dosed at 1.0 to 1.3 molar equivalent relative to required API batch size; final quantity may change based on target yield, purity targets, and process scale.

Downstream process integration

• Introduced after primary ring structure assembly as the oxygenated intermediate in multi-step HPLC-guided synthesis prior to API formation.

Final product types

• Prednisolone API
• Methylprednisolone API
• Combination steroid APIs for anti-inflammatory tablets and injectables

2. Bulk Steroid Derivative Formulation for Veterinary Pharmaceuticals

Veterinary pharmaceutical manufacturers utilize this compound as a key building block in the synthesis of anti-inflammatory agents and hormone modulators used for livestock and companion animals. Contractors require a precisely controlled intermediate that supports further esterification and formulation processes prior to dose adjustment and product packaging. Stringent residue monitoring and documentation under local veterinary health authorities is required, ensuring traceability for every supplied batch.

Industry compliance standards

• VICH GLs (International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Products)
• EMA-CVMP (Committee for Medicinal Products for Veterinary Use) guidelines
• National Residue Control Plans (EU Regulation 470/2009)
• Veterinary pharmacopoeia standards (e.g., BP Vet, USP Vet)

Typical usage ratio

• Added at 0.8 to 1.1 equivalents per batch; adjustments based on target veterinary API profile and anticipated conversion yield.

Downstream process integration

• Fed into multi-step hydrogenation and subsequent esterification processes; monitored for by-products by GC-MS before blending into finished veterinary drug substances.

Final product types

• Prednisolone acetate for cattle and equine formulations
• Injectable glucocorticoid suspensions
• Veterinary oral anti-inflammatory solutions and tablets

3. Intermediate for Steroid-based Diagnostics Manufacturing

Diagnostic kit producers source this intermediate for the synthesis of steroidal tracers and enzyme-linked immunoassay conjugates used in laboratory and clinical hormone analyses. The tetrahydroxy structure supports further analytical labeling (biotinylation, enzyme conjugation) required for precise steroid quantification in biological samples. Tight control over residue solvents and absence of interfering impurities is essential for consistency in diagnostic reagent performance.

Industry compliance standards

• ISO 13485:2016 for medical device QMS
• CLSI standards for immunoassays
• REACH for substance registration
• EU IVDR (Regulation (EU) 2017/746) for in vitro diagnostic devices

Typical usage ratio

• Processed at 0.2 to 0.5 g per 1 L immunoassay conjugation batch; concentrations tailored for individual analytical kit methodologies.

Downstream process integration

• Introduced prior to derivatization and linkage to detection enzymes (e.g., horseradish peroxidase) or radioactive labels, followed by lyophilization and QC batch release.

Final product types

• Immunoassay standard controls (ELISA kits)
• Labeled steroid analytical reagents
• Calibrators for automated biochemical analyzers

4. Advanced Intermediate for Custom Steroid Analog Research and Development

Custom synthesis clients in research institutions and specialty pharma employ this tetrahydroxy pregnadiene to generate analog libraries and probe compounds. Its defined oxygenation pattern allows medicinal chemists to explore SAR (Structure-Activity Relationship) modifications for new anti-inflammatory or immunosuppressive entities. Each lot supports project-based syntheses needing strict impurity profiling and traceability for intellectual property filings and preclinical studies.

Industry compliance standards

• GLP (Good Laboratory Practice) as per OECD guidelines
• Local Institutional Chemical Safety Reviews
• Material Transfer Agreements (MTA) for research supply
• Documented batch records and traceability under research-grade QC

Typical usage ratio

• Dosed at 10–100 mg scale for bench-top transformations or 0.1–0.3 molar equivalents in preparative runs, adjusted per synthetic target.

Downstream process integration

• Applied directly into site-selective oxidation, functional group transformation, or coupling reactions within R&D synthesis workflows, with full analytical monitoring.

Final product types

• Steroidal analog libraries
• Patentable lead compound candidates
• Preclinical evaluation materials